UTHR United Therapeutics Corporation - Common Stock

Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) jumped 13.6% in the afternoon session after a federal district court ruled that competitor Liquidia Corporation infringed patent claims covering United Therapeutics' inhaled treprostinil treatments.

A district judge ruled Wednesday that Liquidia infringed on United Therapeutics' patents with its drug, Yutrepia. The stocks diverged.

Investing.com -- Liquidia Corp shares fell Wednesday after a U.S. District Court in Delaware ruled the company infringed two patent claims held by United Therapeutics Corp. United Therapeutics shares rose more than 13%.

Goldman Sachs analyst Andrea Newkirk initiated coverage of United Therapeutics Corporation (NASDAQ:UTHR) on September 24, 2026, with a Sell rating and a $321 price target. The firm argues that shares trade above their historical valuation range while the core franchise shrinks, and that the market underestimates how hard the idiopathic pulmonary fibrosis (IPF) launch will […]

Earlier this week, Goldman Sachs initiated coverage of United Therapeutics with a Sell rating, even as the company pursues an ambitious pipeline of 14 potential launches, including nebulized Tyvaso for idiopathic pulmonary fibrosis and once-daily oral ralinepag, alongside a US$2.00 billion share repurchase authorization. At the same time, United Therapeutics is pushing ahead with long-horizon xenotransplantation efforts, including a xenokidney registration trial that management aims to...

United Therapeutics (UTHR) moved into focus after Goldman Sachs started coverage with a Sell rating, sending the stock down 4%, a meaningful single session move for a relatively steady biotech stock. Goldman’s call lands after a choppy stretch for United Therapeutics, with the share price down 7.76% over 30 days and 12.75% over 90 days, even though the 1-year total shareholder return of 9.89% and 3-year total shareholder return of 110.50% point to longer term momentum that appears...

United Therapeutics (NASDAQ:UTHR) outlined plans to expand its pulmonary fibrosis, pulmonary hypertension and organ-manufacturing businesses at the Bernstein Healthcare Leaders and Disruptors Conference, with management describing a pipeline of 14 prospective product launches and continued share rep

Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) fell 4% in the afternoon session after Goldman Sachs initiated coverage of the stock with a Sell rating.

CoreWeave upgraded, Etsy downgraded: Wall Street's top analyst calls

Liquidia's Yutrepia posts rapid sales growth, but intensifying competition from established therapies and emerging drugs could test its momentum.

UTHR, NMRA, and EWTX are drawing attention from options bears

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook.

Altimmune (ALT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

United Therapeutics Corporation (NASDAQ:UTHR) committed the remaining $477.6 million under its $2 billion authorization to an accelerated share repurchase with Citibank, N.A. on September 8. Earlier transactions included $1.5 billion of accelerated repurchases and $22.4 million of open-market purchases. The upfront payment was scheduled for around September 10, with initial delivery representing approximately 75% of […]

Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug.

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including United Therapeutics (NASDAQ:UTHR) and its peers.

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FDA accepts United Therapeutics' Tyvaso sNDA for an IPF label expansion, backed by TETON data showing improved lung function and reduced clinical worsening.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

United Therapeutics Corp. continues its investment in New Hampshire’s life science industry with the purchase of the former Anheuser-Busch brewery on the Daniel Webster Highway in Merrimack for $47.5 million. The Maryland-based public benefit corporation closed on the nearly 300-acre property on Tuesday afternoon, according to the Hillsborough County Registry of Deeds. The company has offices ...

Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.

UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

United Therapeutics (UTHR) is back in focus after the FDA accepted its New Drug Application for ralinepag, an investigational once daily oral prostacyclin for pulmonary arterial hypertension, with a target action date set for June 24, 2027. See our latest analysis for United Therapeutics. The ralinepag filing comes after a strong run for United Therapeutics, with the stock delivering a 67.95% total shareholder return over the past year even as the 90 day share price return declined 11.33%...

United Therapeutics stock has delivered a strong 142.7% return over the past 5 years, and the latest valuation checks suggest the shares may still be pricing in more value than the current market level implies. A 142.7% gain over 5 years points to investors already being rewarded for staying invested in United Therapeutics. This makes the current entry point more sensitive to how much value is left on the table. Progress in studies such as the fully enrolled TETON-PPF trial for inhaled...

United Therapeutics Corporation (NASDAQ:UTHR) has moved ralinepag into formal FDA review after the regulator accepted its New Drug Application for the investigational pulmonary arterial hypertension treatment. The FDA filing acceptance establishes a Prescription Drug User Fee Act (PDUFA) target action date of June 24, 2027, giving investors a defined regulatory catalyst following positive Phase 3 results.

The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.

United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional indication, PPF, with top-line results expected in the second half of 2027.

United Therapeutics reported second quarter results that modestly exceeded Wall Street’s revenue and adjusted EPS expectations, with management highlighting the impact of competitive dynamics in the inhaled prostacyclin market. CEO Dr. Martine Rothblatt emphasized progress in the company’s clinical programs, particularly the ADVANCE OUTCOMES study for ralinepag and the TETON-1 trial for Tyvaso in pulmonary fibrosis. President Michael Benkowitz noted that although revenue was flat sequentially, o

Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.

Moby summary of BETA Technologies, Inc.'s Q2 2026 earnings call

BETA Technologies Inc (BETA) reports record Q2 revenue and nearly hits $4B backlog target, while navigating certification progress and significant cash burn.

CEO Rothblatt calls H1 2026 "one of the most consequential periods" in company history.

Liquidia topped Wall Street's second-quarter expectations Wednesday as sales of its lung disease treatment, Yutrepia, grew by double digits.

Management has just raised the peak-sales estimate, and a large slice of it belongs to a drug still running Phase III trials.

In the past week, United Therapeutics reported second-quarter 2026 results showing sales of US$783.3 million, a slight year-on-year decline, while net income rose to US$333 million and diluted EPS increased to US$7.27, alongside continued share repurchases under its US$1.50 billion buyback program. At the same time, publication of positive phase 3 ADVANCE OUTCOMES data for investigational PAH therapy ralinepag and its recent FDA filing added a new layer of potential to United Therapeutics’...

MannKind's (MNKD) increasingly diversified portfolio is seen bringing in higher revenue in H2, with

United Therapeutics' (UTHR) Q2 miss for Tyvaso reflected pressure from rising competition, though th

UTHR tops Q2 EPS estimates, misses revenues, while advancing Tyvaso and ralinepag programs that reshape future growth.

Moby summary of United Therapeutics Corporation's Q2 2026 earnings call

Company advances key regulatory submissions for Tyvaso and ralinepag while navigating competitive pressures in the inhaled prostacyclin market.

United Therapeutics (NASDAQ:UTHR) reported second-quarter 2026 revenue of approximately $783 million, essentially flat from the first quarter, as competitive pressure affected sales of its nebulized TYVASO therapy. Company executives said they expect stronger performance in the second half of the ye

Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

United Therapeutics (UTHR) delivered earnings and revenue surprises of +6.60% and -2.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Biotechnology company United Therapeutics (NASDAQ:UTHR) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, but sales fell by 1.9% year on year to $783.3 million. Its GAAP profit of $7.27 per share was 5.9% above analysts’ consensus estimates.

UTHR vs. SDZNY: Which Stock Is the Better Value Option?

(Bloomberg) -- Executives and investors tied to the AI supply chain were among the biggest insider sellers in the second quarter, taking advantage of a sharp — and volatile — rally in technology stocks.Most Read from BloombergUS Intercepts Iran Attack on Bases, Puncturing Days of CalmSK Hynix Profit Disappoints, Spending Soars to $31 BillionNvidia’s $750 Billion in Deals Reignite Circular AI FearsChip Rout Deepens on Circular Funding, China Competition FearsApple Set to Make Big Smart Home Push

Martine Rothblatt exercised options at $135.42 and sold at $530.42 under a pre-established Rule 10b5-1 plan, reducing her stake by just 1% while maintaining $353.1 million in equity value.

Liquidia's Yutrepia launch is fueling rapid growth, outperforming United Therapeutics on estimates and share gains despite a higher valuation.